GlobeNewswire

Skybox Security Expands Footprint in APAC with New Channel Partners and Leadership in Australia

Dela

SAN JOSE, Calif., June 19, 2018 (GLOBE NEWSWIRE) -- Skybox(TM) Security, a global leader in cybersecurity management, today announced that two Australia-based firms, NEXTGEN and Insentra have joined its Australia channel partner program. In addition, Skybox has filled a key leadership role in Australia and New Zealand, continuing the company's expansion in the Asia Pacific region (APAC), which is among the company's fastest-growing global markets.

The Skybox APAC channel program enables managed security service providers (MSSPs), value-added resellers (VARs), distributors and system integrators to meet the needs of the market by deploying and offering services that leverage the Skybox(TM) Security Suite. By adding the Suite to their offerings, local partners can continue to serve as trusted cybersecurity advisors to Australian businesses.

"Skybox is working with many of the world's largest, most complex networks, providing security teams with the visibility and context needed to address vulnerabilities and other security weaknesses. This means organisations are able to better manage their attack surface and reduce the risk of a breach," said Gerry Sillars, VP of APAC. "In this region, the demand for our solution is driven by a strong desire for improved network visibility and increased demand for our threat-centric vulnerability management (TCVM) solution. Our solution has proven to be a differentiator for our resellers, and so we've been able to quickly grow our partner ecosystem in expansion markets."

According to the Australian Cyber Security Centre's (ACSC) 2017 Threat Report, "Cyber espionage and cybercrime remain the primary threats to the Australian private sector, affecting Australia's competitive advantage, particularly in the specialist and profitable area of research and development." Through local partners, Skybox can offer Australian enterprises a security management platform that delivers comprehensive attack surface visibility and enables unified vulnerability management and firewall and security policy management across their entire network, including in physical, multi-cloud and OT environments.

"Skybox solutions are an ideal fit for NEXTGEN's advanced enterprise software strategy. As cybersecurity continues to be a critical focus in IT, we're excited to partner with Skybox to provide a best-in-class solution to manage this environment. We have been acknowledged at a global level for our innovative approach to distribution. It's what we call 'distribution reinvented' - and it relies on strategic partnerships with leading technology providers such as Skybox," said John Walters, group CEO for NEXTGEN.

"Insentra is thrilled to be joining the Skybox channel program as APAC's first Services Delivery Partner working with the Australia / New Zealand team under Tom Castell's leadership," said Ronnie Altit, CEO for Insentra. "This partnership will see Insentra provide professional services capabilities in Australia and New Zealand to Skybox partners, shortening the time-to-value for their customers."

In addition to new partnerships, Skybox has recently appointed a new regional sales director for Australia and South Pacific, Tom Castell. Castell has more than 12 years of experience in the IT security market with the last eight years focused on the Australia market. Prior to joining Skybox, he worked for Mimecast leading their go-to-market strategy, working with large enterprise accounts across Australia, New Zealand and most recently all of APAC.

To learn more about the Skybox Partner Program and the advantages of working with a Skybox partner visit: https://www.skyboxsecurity.com/partners/overview

About Skybox Security
www.skyboxsecurity.com

Skybox provides the industry's broadest cybersecurity management platform to address security challenges within large, complex networks. By integrating with over 120 networking and security technologies, the Skybox(TM) Security Suite gives comprehensive attack surface visibility and the context needed to quickly identify and fix vulnerabilities and security weaknesses. Our analytics, automation and intelligence improve the efficiency and performance of security operations in vulnerability and threat management and firewall and security policy management for the world's largest organisations.

About NEXTGEN
nextgendistribution.com.au

NEXTGEN responded to an evolving ANZ IT ecosystem with an advanced enterprise software strategy, best-in-breed infrastructure, and select services ranging from marketing to payment solutions tailored to the needs of the channel. We're proactively out in the marketplace seeking out and facilitating opportunities that bring vendors and partners together. We're the connection between the vendors and the channel and we'll help where we can to move an opportunity through the lifecycle to make it a bigger, better and more robust solution.

For more information on NEXTGEN and the partnership with Skybox Security please contact: john.walters@nextgendistribution.com.au

About Insentra
www.insentra.com.au

Insentra is a collaborative IT services partner delivering a range of specialised professional and managed services transacting exclusively through the IT channel. We focus on attaining knowledge and skills in solutions to best empower the channel. Our partner-centric business model provides our partners and their clients with access to industry expertise and accountable outcomes. We are and always will remain a partner obsessed company.

© 2018 Skybox Security, Inc. All rights reserved. Skybox Security and the Skybox Security logo are either registered trademarks or trademarks of Skybox Security, Inc., in the United States and/or other countries. All other trademarks are the property of their respective owners. Product specifications subject to change at any time without prior notice.

CONTACT INFORMATION

Tawnya Lancaster
Director of Communications
Skybox Security
408.205.1618
Tawnya.lancaster at skyboxsecurity.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Skybox Security via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Aprea Therapeutics has received FDA Orphan Drug Designation and Fast Track Designation for APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, April 16, 2019. Karolinska Development's portfolio company Aprea Therapeutics has from FDA received an Orphan Drug Designation for APR-246 for the treatment of patients with Myelodysplastic Syndromes (MDS) having a TP53 mutation. In addition, FDA has also granted Fast Track Designation to APR-246 for treatment of MDS. Orphan Drug Designation is granted by the FDA Office of Orphan Products Development to advance the evaluation and development of safe and effective therapies for the treatment of rare diseases. The designation can provide development and commercial incentives for designated compounds and medicines, including eligibility for a seven-year period of market exclusivity in the U.S. after product approval, FDA assistance in clinical trial design, tax credits related to clinical trial expenses, and an exemption from FDA user fees. The FDA's Fast Track program facilitates the development of drugs intended to treat serious conditions and that have the potential to addre

Karolinska Developments portföljbolag Aprea Therapeutics har fått särläkemedelsstatus och snabbspårstatus från FDA för APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, SVERIGE - 16 april 2019. Karolinska Development AB meddelar idag att portföljbolaget Aprea Therapeutics har av FDA fått särläkemedelsstatus för APR-246 för behandling av patienter med TP53-muterad myelodysplastiskt syndrom (MDS). Dessutom ger FDA bolaget snabbspårstatus (Fast Track Designation), för APR-246 för behandling av MDS. Amerikanska läkemedelsverket, FDA, ger särläkemedelsstatus till läkemedelskandidater för att snabba på utvärderingen och utvecklingen av säkra och effektiva behandlingar av ovanliga sjukdomar. Särläkemedelsstatus ger företag både regulatoriska och kommersiella incitament genom att läkemedlet får marknadsexklusivitet på den amerikanska marknaden i sju år efter marknadsgodkännande samtidigt som företaget får stöd från FDA när det gäller designen av kliniska prövningar, skatteförmåner för kostnader kopplade till kliniska prövningar och avgiftsbefrielse från FDA. FDA:s snabbspår underlättar utvecklingen av läkemedel som är avsedda för att behandla allva

Bergman & Beving AB: Bergman & Beving förvärvar KGC10.4.2019 14:00:00 CESTPressmeddelande

Pressmeddelande Bergman & Beving förvärvar KGC Bergman & Beving har idag tecknat avtal om förvärv av samtliga aktier i KGC Verktyg & Maskiner AB. KGC, med säte i Älvsjö, har i mer än 60 år utvecklat och levererat kvalitetsverktyg och tillbehör för murning och plattsättning i det egna varumärket KGC. Bolaget omsätter cirka 80 MSEK per år, och har 24 anställda. "KGC är ett ledande varumärke med högt anseende hos murare och plattsättare och har en mycket stark ställning på den svenska marknaden", säger Pontus Boman, VD och koncernchef. Tillträde beräknas ske den 1 maj 2019 och förvärvet bedöms ha en marginellt positiv påverkan på Bergman & Bevings resultat per aktie under innevarande räkenskapsår. Stockholm den 10 april 2019 Bergman & Beving AB (publ) För ytterligare information kontakta: Pontus Boman, VD & Koncernchef, telefon 010-454 77 00 Peter Schön, CFO, telefon 070-339 89 99 Denna information lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den 10 april 201

Bergman & Beving AB: Bergman & Beving acquires KGC10.4.2019 14:00:00 CESTPressmeddelande

Press release Bergman & Beving acquires KGC Bergman & Beving has today signed an agreement to acquire all shares in KGC Verktyg & Maskiner AB. KGC, based in Älvsjö, has for more than 60 years developed and delivered quality tools and accessories for bricklayers and tilers in its own brand KGC. The business has a turnover of approximately SEK 80 million per year, and has 24 employees. "KGC is a leading brand with high reputation among bricklayers and tilers and has a very strong position in the Swedish market," says Pontus Boman, President and CEO. The closing is taking effect on 1 May 2019 and the acquisition is expected to have a marginal positive impact on Bergman & Beving's earnings per share during the current fiscal year. Stockholm, 10 April 2019 Bergman & Beving AB (publ) For further information, please contact: Pontus Boman, President & CEO, Tel: +46 10 454 77 00 Peter Schön, CFO, Tel: +46 70 339 89 99 The information was submitted for publication, through the agency of the cont

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum